All In Biotech

Free tool

FAERS Monitor: Visine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020485 or its brand name (Visine, Naphazoline Hydrochloride, Pheniramine Maleate). Reports on generic versions are filed under their own applications.

Reports

25

Serious

2

8% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation10
  • mydriasis7
  • product use in unapproved indication7
  • eye pain6
  • expired product administered3
  • vision blurred3
  • eye swelling2
  • adverse event1
  • drug ineffective1
  • eye allergy1
  • eye pruritus1
  • incorrect dose administered1
  • lacrimation increased1
  • ocular discomfort1
  • ocular hyperaemia1

Reports by year received

View as table
YearReports
20151
20171
20201
202411
20259
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,134 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye allergy1543.779.6135
mydriasisSignal7459.2244.92,759
eye irritationSignal10146.290.41,304
eye painSignal689.544.5441
expired product administeredSignal375.926.3153
ocular discomfort174.911.018
eye swelling245.212.048
lacrimation increased127.84.16
eye pruritus125.03.75
product use in unapproved indicationSignal723.812.7132
vision blurredSignal318.46.434
ocular hyperaemia117.72.63
adverse event19.11.31
incorrect dose administered13.70.50
drug ineffective10.60.10

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.